ResurFX
ResurFX is a non-ablative fractional laser, meaning it can emit powerful light energy without visibly damaging the outer layer of skin. The fact that it is a fractional device means that it emits energy in a dotted pattern that leaves some skin undamaged, resulting in less discomfort and downtime. The laser is applied to create controlled thermal damage and micro-injuries. As these micro-injuries heal, new collagen and elastin are produced, resulting in resilient, glowing skin.
Dr. Day will use her Lumenis M22 laser to perform the ResurFX treatment to treat a wide range of issues such as age spots or sun spots, fine lines and wrinkles, stretch marks or striae, hyperpigmentation and uneven skin tone, scars from acne or surgery, and loose skin.
ResurFX is a fractional, non-ablative treatment. As a result, patients receiving this treatment do not have to prepare for the more extensive and uncomfortable healing time associated with other resurfacing treatments. Patients receiving this treatment will come in for topical numbing prior to treatment, alleviating any discomfort during the actual treatment. The patient will experience initial redness immediately after treatment, which will go down a few hours post treatment and then redness might be prominent for a few days post-treatment. Dr. Day will recommend specific post-care products to minimize healing time and maximize results.
Estrogen Study
This study is being done to see whether applying a cream with estradiol (a form of estrogen) to the face can improve overall skin quality and help reduce fine lines and wrinkles in peri- and post-menopausal women, and how this relates to epigenetic changes in the skin. A part of the study will also include applying an extra rapamycin analog cream to the face, which is also believed to improve overall skin quality and help reduce fine lines and wrinkles.
WHY THIS MATTERS
Skin aging in peri- and post-menopausal women is deeply tied to hormonal shifts. This study explores whether topical estradiol can turn back the clock – cellularly.
Eligibility
You MAY qualify if you can answer YES to all:
I am a healthy female (peri or menopausal) between the ages of 40 and 65.
I have not had any cosmetic facial treatments in the last 1-3 months.
I have not had any GLP-1 treatments in the last 6 months.
Study Design and Duration
The study includes daily evening application of study cream for 12 weeks, followed by 4 weeks with no test product use. In total, the study will last 16 weeks or approximately 4 months.
Topical Scalp Serum Containing RLX‑201 in Subjects With Mild‑to‑Moderate Hair Thinning
Purpose of the Study
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of a scalp serum containing RLX‑201 when applied once daily for 20 weeks in men and women with mild‑to‑moderate hair thinning. The study will assess changes in hair density, hair thickness, and overall scalp health using clinical evaluations, imaging tools, and participant self‑assessments.
Eligibility
You MAY qualify if you can answer YES to all:
I am a healthy male or female between the ages of 30 and 60.
Self‑perceived mild‑to‑moderate hair thinning.
I have NOT used minoxidil, light therapy, or other hair growth treatments within 3 months.
I have NOT used medications affecting hair growth (e.g., finasteride, spironolactone, cyproterone acetate, 5‑alpha‑reductase inhibitors) or a GLP-1 within 6 months.
Study Design and Duration
This is a single‑center clinical study lasting approximately 20 weeks. If you agree to participate, you will be asked to attend study visits at the following time points: Baseline, and Weeks 2, 4, 8, 12, 16, and 20.